Corbus Pharmaceuticals Holdings (CRBP) EBT (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly EBT of -$24.4 million for Q3 2025, down 34.86% year-over-year from -$37.5 million in Q3 2024, and down 27.49% quarter-over-quarter from -$19.2 million in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) EBT (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' EBT history runs 13 years deep, the most recent figure standing at -$24.4 million for Q3 2025.
- In Q3 2025, EBT fell 34.86% year-over-year to -$24.4 million; the TTM figure through Sep 2025 stood at -$78.9 million (down 26.36% YoY), while the FY2024 annual figure was -$51.5 million, up 63.19% from the prior year.
- EBT for Q3 2025 stood at -$24.4 million, down from -$19.2 million in the prior quarter.
- The five-year high for EBT was -$9.2 million in Q1 2022, with the low at -$54.0 million in Q2 2021.
- The 5-year median for EBT is -$19.2 million (2022), against an average of -$23.8 million.
- The sharpest annual moves came in 2022 and 2025: EBT jumped 82.22% in 2022, then plunged 118.07% in 2025.
- Corbus Pharmaceuticals Holdings' EBT stood at -$10.4 million in 2021, then slipped by 19.68% to -$12.5 million in 2022, then increased by 14.11% to -$10.7 million in 2023, then slipped by 16.86% to -$12.5 million in 2024, then tumbled by 94.82% to -$24.4 million in 2025.
- Business Quant data shows CRBP's EBT at -$24.4 million in Q3 2025, -$19.2 million in Q2 2025, and -$22.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -24.42 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -22.82 Mn |
| Dec 31, 2024 | -12.53 Mn |
| Sep 30, 2024 | -18.11 Mn |
| Jun 30, 2024 | -23.16 Mn |
| Mar 31, 2024 | -10.46 Mn |
| Dec 31, 2023 | -10.73 Mn |
| Sep 30, 2023 | -30.31 Mn |
| Jun 30, 2023 | -28.96 Mn |
| Mar 31, 2023 | -18.23 Mn |
| Dec 31, 2022 | -12.49 Mn |
| Sep 30, 2022 | -19.16 Mn |
| Jun 30, 2022 | -23.16 Mn |
| Mar 31, 2022 | -9.20 Mn |
| Dec 31, 2021 | -10.43 Mn |
| Sep 30, 2021 | -52.68 Mn |
| Jun 30, 2021 | -53.96 Mn |
| Mar 31, 2021 | -51.75 Mn |
| Dec 31, 2020 | -21.48 Mn |